DoJ adds weight to Abbott whistleblower suit

The Justice Department is joining a whistleblower suit against Abbott Laboratories that alleges the drugmaker promoted its seizure drug Depakote for off-label uses. Former employees claim Abbott touted Depakote for patients with dementia and Alzheimer's disease, training its reps to push the drug off-label and using doctor seminars to promote it for unapproved uses.

The allegations aren't new; Abbott disclosed more than a year ago the feds were looking into its Depakote marketing practices. But as Pharmalot reports, by joining this whistleblower suit, the DoJ intensifies the pressure on Abbott--and signals that investigators believe the allegations may have merit.

Off-label marketing investigations have been the bane of Big Pharma over the past couple of years, as top drugmakers have agreed to pay hundreds of millions--even billions--to settle claims that they pushed products for uses not approved by the FDA. That's illegal, of course, and in some cases--such as Pfizer's $2.3 billion settlement of marketing claims involving its painkiller Bextra and several other drugs--company subsidiaries have pleaded guilty to criminal charges.

- read the Pharmalot post

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.